Prognostic factors in high and intermediate grade non-Hodgkin's lymphoma
Open Access
- 1 February 1989
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 59 (2) , 276-282
- https://doi.org/10.1038/bjc.1989.57
Abstract
An analysis of prognostic factors has been performed on 260 patients with high and intermediate grade non-Hodgkin's lymphoma (NHL) treated over an 11-year period between 1975 and 1986. The overall 5-year survival rate was 50% with a median follow-up of 72 months. Over 20 clinical, radiological and laboratory parameters have been studied, including variables reported to be important indicators of prognosis in previous series, and these variables have been subjected to univariate and multivariate analysis. Attainment of complete remission (CR) was the most important predictor of overall survival, low serum lactate dehydrogenase (LDH), limited stage disease and a high serum albumin were also independently associated with prolonged survival in multivariate analysis. After removing remission status from the model, Ann Arbor clinical stage became the most significant pre-treatment prognostic indicator. Sixty-five per cent of patients achieved CR, and a discriminant analysis showed that failure to attain CR was associated with advanced stage disease, constitutional symptoms, increasing patient age, a low serum albumin and the presence of bulk disease. Advanced clinical stage and an elevated serum LDH predicted independently for a poor relapse-free survival, and reduced overall survival following CR. There was no significant correlation between histological subtype in the Kiel classification and prognosis. This study confirms the prognostic significance of remission status and Ann Arbor clinical stage, and illustrates additional factors including serum levels of albumin and LDH, which serve to enhance the pre-treatment prognostic evaluation of patients with unfavourable histology NHL.Keywords
This publication has 31 references indexed in Scilit:
- Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry.Journal of Histochemistry & Cytochemistry, 1983
- Prognostic Value of Serum Lactic Dehydrogenase in Non‐Hodgkin's LymphomaScandinavian Journal of Haematology, 1983
- Diffuse Aggressive Lymphomas: Increased Survival After Alternating Flexible Sequences of ProMACE and MOPP ChemotherapyAnnals of Internal Medicine, 1983
- Treatment of advanced diffuse histiocytic lymphoma: An analysis of prognostic variablesCancer, 1982
- THE CLINICAL-SIGNIFICANCE OF THE MORPHOLOGICAL SUBDIVISION OF DIFFUSE HISTIOCYTIC LYMPHOMA - A STUDY OF 162 PATIENTS TREATED BY THE SOUTHWEST ONCOLOGY GROUP1982
- FACTORS PREDICTING LONG-TERM SURVIVAL IN DIFFUSE MIXED, HISTIOCYTIC, OR UNDIFFERENTIATED LYMPHOMA1981
- Intensive combination chemotherapy with vincristine, adriamycin and prednisolone (VAP) in the treatment of diffuse histology non-hodgkin's lymphomaPublished by Elsevier ,1980
- Cyclophosphamide, Vincristine, Methotrexate with Leucovorin Rescue, and Cytarabine (COMLA) Combination Sequential Chemotherapy for Advanced Diffuse Histiocytic LymphomaAnnals of Internal Medicine, 1980
- SERUM LACTIC-DEHYDROGENASE AS A PROGNOSTIC TOOL FOR NON-HODGKIN LYMPHOMAS1979
- CORRELATION OF SERUM LACTIC DEHYDROGENASE ACTIVITY WITH THE CLINICAL STATUS OF PATIENTS WITH CANCER, LYMPHOMAS, AND THE LEUKEMIAS1957